Full history for every metric is available with a Kvantra account
Karuna Therapeutics, Inc. (KRTX)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 37 | 11 | 1 | 1 |
| Operating profit | $m | -495 | -495 | |||||
| Net profit | $m | -18 | -45 | -69 | -144 | -276 | -434 | -422 |
| EPS reported | $ | -11.73 | -11.39 | |||||
| Operating cashflow per share | $ | -10.44 | -10.44 | |||||
| Capex per share | $ | 0.08 | 0.08 | |||||
| FCF per share | $ | -10.52 | -10.52 | |||||
| Free cash flow | $m | -389 | -389 | |||||
| Net debt | $m | -1,246 | -1,263 | |||||
| Book value equity | $m | 1,254 | 1,254 | |||||
| Book value per share | $ | 33.94 | 33.20 | |||||
| Number of shares | m | 36.96 | 37.78 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 9.33 | 10.05 | |||||
| P/S LTM | x | 17,886.71 | 19,264.95 | |||||
| P/FCF LTM | x | -30.09 | -32.41 | |||||
| EV/EBITDA LTM | x | -23.38 | -24.37 | |||||
| EV/Sales LTM | x | 17,628.09 | 17,334.04 | |||||
| Earnings Yield LTM | % | -3.71% | -3.56% | |||||
| FCF Yield | % | -3.32% | -3.09% | |||||
| Quality | ||||||||
| ROE | % | -34.58% | -36.44% | |||||
| ROIC | % | -38.93% | -38.93% | |||||
| Operating margin | % | -75654.0% | -75654.0% | |||||
| Gross margin | % | -160.09% | -160.09% | |||||
| FCF/Sales | % | -59439.8% | -59439.8% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -93.85% | -93.85% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -23.29 | -23.29 | |||||
| Net Debt/EBITDA | x | 0.34 | 0.34 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -10.65% | -10.02% | |||||
| Net debt/Equity | x | -0.99 | -1.01 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT is being evaluated for several indications: the treatment of acute psychosis in schizophrenia patients, the amelioration of central nervous system conditions (including the negative and cognitive symptoms associated with schizophrenia and general psychosis), and the management of dementia-related psychosis. Beyond KarXT, the firm is also advancing a pipeline of other drug candidates that interact with muscarinic receptors. Karuna Therapeutics, Inc. has forged several strategic partnerships, encompassing licensing agreements with Eli Lilly and Company and Zai Lab (Shanghai) Co., Ltd., a patent license with PureTech Health LLC, and drug discovery collaborations with Charles River Laboratories and PsychoGenics, Inc. Established in 2009, the enterprise initially operated under the name Karuna Pharmaceuticals, Inc., before officially adopting its current corporate identity, Karuna Therapeutics, Inc., in March 2019. Its corporate headquarters are located in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Karuna Therapeutics, Inc. (KRTX)
Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT is being evaluated for several indications: the treatment of acute psychosis in schizophrenia patients, the amelioration of central nervous system conditions (including the negative and cognitive symptoms associated with schizophrenia and general psychosis), and the management of dementia-related psychosis. Beyond KarXT, the firm is also advancing a pipeline of other drug candidates that interact with muscarinic receptors. Karuna Therapeutics, Inc. has forged several strategic partnerships, encompassing licensing agreements with Eli Lilly and Company and Zai Lab (Shanghai) Co., Ltd., a patent license with PureTech Health LLC, and drug discovery collaborations with Charles River Laboratories and PsychoGenics, Inc. Established in 2009, the enterprise initially operated under the name Karuna Pharmaceuticals, Inc., before officially adopting its current corporate identity, Karuna Therapeutics, Inc., in March 2019. Its corporate headquarters are located in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free